AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01364610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
Study NCT01724606 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT)
Description: WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
Study NCT01724606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
Study NCT03421223 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03836638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 Units of botulinum toxin
Description: 30 Units of botulinum toxin to upper face
Study NCT03836638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 Units of botulinum toxin
Description: 50 Units of botulinum toxin to upper face
Study NCT03438656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
Study NCT02088580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple Chronotherapy
Study NCT04366544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Part B:
Description: EEG and fMRI
Study NCT00834132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg Tablet
Description: 1 x 600mg, single-dose fed
Study NCT00834132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® 600 mg Tablet
Description: 1 x 600mg, single-dose fed
Study NCT03075943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InSea2
Description: Daily supplement: 2 capsules of InSea2
Study NCT03075943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplement: 2 capsules of Placebo
Study NCT01155310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium/Oxygen 78%/22%
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.
Study NCT01155310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air/Oxygen
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.
Study NCT00712075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST+PDA
Description: PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
Study NCT00712075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training
Description: Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
Study NCT00712075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDA-only
Description: To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
Study NCT02660346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
Study NCT02660346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
Study NCT02660346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Control Arm Treatment
Study NCT01665495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended pericardial drainage by catheter
Description: Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
Study NCT02660346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Study Arm Treatment
Study NCT02792946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebrophylline
Study NCT02792946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acebrophylline
Study NCT03686722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is used primarly in treatment of diabetes type II
Study NCT03686722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is used primarly in treatment of diabetes type II
Study NCT03686722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatsvir is a direct acting antiviral drug
Study NCT03004131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride + fluticasone propionate nasal spray
Study NCT03004131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03004131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate nasal spray + loratadine
Study NCT01401205 — intervention group
Intervention type: OTHER
Intervention: upper airway ultrasonographic examination
Description: upper airway ultrasonographic examination and cuff leak test
Study NCT02436200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
Study NCT00186992 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: image-guided radiotherapy
Description: Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
Study NCT01725308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).
Study NCT01725308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken by mouth (orally).
Study NCT01725308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken by mouth (orally).
Study NCT00545948 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine followed by Cisplatin
Description: Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
Study NCT00545948 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed followed by Cisplatin
Description: Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
Study NCT00675779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive (Mercilon)
Description: oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
Study NCT04128228 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8-week outpatient treatment
Description: Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
Study NCT03285893 — intervention group
Intervention type: OTHER
Intervention: oral cell DNA adducts
Description: oral cells will be collected, DNA isolated, and analyzed for adducts
Study NCT00675779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin + oral contraceptive
Description: atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
Study NCT02796547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Infiltration of the banks of the episiotomy done with Levobupivacaine
Study NCT02796547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: Infiltration of the banks of the episiotomy done with physiological serum
Study NCT01079858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657 (ORB Preserved Ocular Emulsion)
Description: Patients will dose as needed throughout the day (PRN) for 4 weeks.
Study NCT04708691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercise
Study NCT03954730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
Study NCT03954730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Release Technique
Description: Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
Study NCT03221296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Training (Intervention Group)
Description: Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active outreach
Description: Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointments
Description: Participants in the enhanced-care intervention will be given specific appointment times/dates.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial support
Description: Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microenterprise
Description: YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Description: Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
Study NCT03966586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical care and counseling
Description: Usual clinical care and counseling
Study NCT02226016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FG-5000A
Description: a measuring device for the assessment of levator muscle strength
Study NCT02554643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Nutrition intervention, once a week during 12 weeks
Study NCT02554643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer
Description: Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
Study NCT02554643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer
Description: Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
Study NCT02554643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running
Description: Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
Study NCT02554643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running
Description: Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
Study NCT01260805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Drug
Description: Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Study NCT01260805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Drug
Description: Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Study NCT02282124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program with monthly sessions
Description: Patients participate in 9 sessions during the first 8th month after transplantaiton
Study NCT03797326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W.
Study NCT03797326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally once a day during each 21-day cycle.
Study NCT00939172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP607
Description: 3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
Study NCT04701281 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intra-arterial LIOX + Capecitabine
Description: 5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
Study NCT04762355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
Study NCT04762355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Placebo-to-match palovarotene ophthalmic solution vials
Study NCT00552799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin VK
Description: Biconcave tablet 250mg oral, b.d.
Study NCT00552799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: biconcave tablet matching active comparator as much as possible in size and shape
Study NCT02964104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered once weekly subcutaneously (s.c., under the skin) for 35 days
Study NCT02964104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered once daily subcutaneously for 35 days
Study NCT02964104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily subcutaneously for 35 days
Study NCT02964104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered once weekly subcutaneously for 35 days
Study NCT03199911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibiotic Product
Description: Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
Study NCT03199911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Non-Antibiotic Ointment
Description: Mineral oil/petrolatum-based artificial tear ointment.
Study NCT02690896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCF Caregiver Support Group
Description: The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
Study NCT02690896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Support Groups
Description: Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
Study NCT02282124 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care, containing one session
Description: Session takes place within the first three months after transplantation
Study NCT01124786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01
Description: 1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
Study NCT01124786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
Study NCT04302961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Feedback
Description: Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
Study NCT04302961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Feedback
Description: Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
Study NCT00500201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 60 mg
Description: SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
Study NCT00500201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 120 mg
Description: SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
Study NCT00500201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be administered orally by subjects.